Morgan Stanley 22nd Annual Global Healthcare Conference
Logotype for Treace Medical Concepts Inc

Treace Medical Concepts (TMCI) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Treace Medical Concepts Inc

Morgan Stanley 22nd Annual Global Healthcare Conference summary

22 Jan, 2026

Market trends and competitive landscape

  • Foot and ankle market saw softening in late Q1 and early Q2, attributed to new competitive systems and increased interest in minimally invasive osteotomies.

  • Bunion procedures are elective but tend to be deferred rather than avoided, with strong seasonality and a typically robust Q4.

  • U.S. foot and ankle market growth is estimated at 6%-7%, with bunion market unit growth at 2%-4%.

  • Lapidus procedures have grown from 10%-15% to 30% of bunion cases since 2015; minimally invasive osteotomies are a fast-growing trend within the remaining 70%.

  • MIS osteotomy share is still low due to procedural complexity, but new solutions aim to expand this segment.

Product innovation and commercialization

  • Nanoplasty, a minimally invasive osteotomy solution, is set for limited release in late Q4, with full-scale launch and revenue impact expected in 2025.

  • A second MIS osteotomy platform will follow Nanoplasty, initially available to design surgeons in Q4.

  • SpeedPlate product line expanded with new designs for larger bone fusions and small incision approaches, with further launches planned for early 2025.

  • RedPoint PSI, a personalized surgical planning and cutting guide technology, will expand user access in Q4 and is expected to be fully available in Q1 2025.

  • Ten new products are planned for release between late 2024 and 2025, targeting increased utilization and wallet share.

Reimbursement and facility access

  • Proposed CMS rule changes could double ASC reimbursement for Lapiplasty from $4,500 to $9,700, potentially driving adoption in cost-sensitive settings.

  • 40%-50% of procedures are already reimbursed at higher outpatient rates; new rules could elevate reimbursement for the remaining cases.

  • Commercial payers often follow Medicare trends, amplifying the impact of CMS changes.

  • Facility access is improving, with a menu of technologies at different price points aiding penetration into private ASCs.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more